Central GLP-1R activation in hypothalamic and mesolimbic pathways may lead to fatigue, lethargy, or brain fog 63 , though such effects might be often transient and dose-dependent
This conversation should involve your healthcare provider, who can integrate biomarker data into a comprehensive assessment
This is less commonly observed with Tirzepatide, which lacks glucagon activity
This work was supported by the National Institute on Drug Abuse Intramural Research Program (M.F., G.R.M., M.N.N., V.M., O.A.A., M.A.H., and L.L.) and the National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research (M.F., G.R.M., V.M., and L.L.)
Published in the New England Journal of Medicine, the trial tested retatrutide at doses of 1mg, 4mg, 8mg, and 12mg against placebo over 48 weeks